Literature DB >> 21995398

Vemurafenib in melanoma with BRAF V600E mutation.

Hiroyuki Morita, Ryozo Nagai.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21995398     DOI： 10.1056/NEJMc1108651

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  7 in total

Review 1.  Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy.

Authors:  Renumathy Dhanasekaran; Jean-Charles Nault; Lewis R Roberts; Jessica Zucman-Rossi
Journal:  Gastroenterology       Date:  2018-11-04       Impact factor: 22.682

Review 2.  An evaluation of regulatory and commercial barriers to stratified medicine development and adoption.

Authors:  N A Meadows; A Morrison; D A Brindley; A Schuh; R W Barker
Journal:  Pharmacogenomics J       Date:  2014-10-07       Impact factor: 3.550

Review 3.  Advances in the management of low-grade gliomas.

Authors:  Amulya A Nageswara Rao; Roger J Packer
Journal:  Curr Oncol Rep       Date:  2014       Impact factor: 5.075

4.  Molecular tumor board: the University of California-San Diego Moores Cancer Center experience.

Authors:  Maria Schwaederle; Barbara A Parker; Richard B Schwab; Paul T Fanta; Sarah G Boles; Gregory A Daniels; Lyudmila A Bazhenova; Rupa Subramanian; Alice C Coutinho; Haydee Ojeda-Fournier; Brian Datnow; Nicholas J Webster; Scott M Lippman; Razelle Kurzrock
Journal:  Oncologist       Date:  2014-05-05

Review 5.  Dermatological adverse events from BRAF inhibitors: a growing problem.

Authors:  Viswanath Reddy Belum; Alyssa Fischer; Jennifer Nam Choi; Mario E Lacouture
Journal:  Curr Oncol Rep       Date:  2013-06       Impact factor: 5.075

6.  Insight into molecular dynamics simulation of BRAF(V600E) and potent novel inhibitors for malignant melanoma.

Authors:  Hsin-Chieh Tang; Yu-Chian Chen
Journal:  Int J Nanomedicine       Date:  2015-04-23

7.  Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay.

Authors:  Maria Schwaederle; Hatim Husain; Paul T Fanta; David E Piccioni; Santosh Kesari; Richard B Schwab; Kimberly C Banks; Richard B Lanman; AmirAli Talasaz; Barbara A Parker; Razelle Kurzrock
Journal:  Oncotarget       Date:  2016-03-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.